}; (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));


NEW DELHI: Making a stellar debut, shares of Gland Pharma on Friday surged over 21% on the bourses in comparison with its difficulty value. After opening on a robust notice, the scrip settled with a 7% achieve on each the BSE and the NSE.
On the BSE, the shares opened at Rs 1,701 apiece, a achieve of over 13 per cent in comparison with the difficulty value of Rs 1,500. The inventory touched an intra-day excessive of Rs 1,850 and ended the day at Rs 1,820.45.
Related traits had been witnessed on the NSE the place the scrip listed at Rs 1,710 and touched an intra-day excessive of Rs 1,850. The opening value was 14 per cent extra as in comparison with the difficulty value. It closed at Rs 1,828.
In comparison with the difficulty value of Rs 1,500 apiece, the scrip ended the day with a achieve of greater than 21 per cent on each the bourses.
The worth band for the preliminary public supply (IPO), which closed earlier this month, was fastened at Rs 1,490-1,500 per share. The corporate’s promoters are Fosun Singapore and Shanghai Fosun Pharma.
The supply comprised issuance of contemporary shares value as much as Rs 1,250 crore and a proposal on the market (OFS) of as much as 3,48,63,635 shares.
The OFS consists of sale of as much as 1,93,68,686 shares by Fosun Pharma Industrial Pte Ltd, 1,00,47,435 shares by Gland Celsus Bio Chemical compounds Pvt Ltd, 35,73,014 shares by Empower Discretionary Belief and 18,74,500 shares by Nilay Discretionary Belief.
Gland Pharma raised Rs 1,944 crore from anchor buyers by promoting shares at Rs 1,500 apiece. Authorities of Singapore, Nomura, Goldman Sachs, Morgan Stanley, SBI Mutual Fund, Axis Mutual Fund, SBI Life Insurance coverage Firm and Constancy had been among the many anchor buyers.



Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *